PEER 2: Pelvic nerve recording during Medtronic InterStim sacral neuromodulation
Official title: Pelvic Health Electrically Evoked Recording (PEER) 2 Study
Run by MedtronicNeuro · NCT05200923 · Data updated 2026-11-12
This tests whether recording electrical signals from pelvic nerves during Medtronic InterStim sacral neuromodulation can help guide therapy for adults with overactive bladder, fecal incontinence, or urinary retention.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | MedtronicNeuro Industry-sponsored |
| Locations | 7 sites (Indianapolis, Indiana and 6 other locations) |
| Status | Recruiting |
| Started | January 18, 2022 |
| Main results expected | December 18, 2026 |
| Study ends | December 18, 2026 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT05200923 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who are candidates for or undergoing Medtronic InterStim lead implantation for overactive bladder, urinary urgency/frequency, fecal incontinence, or urinary retention and who can complete diaries, questionnaires, and study visits.
✕Probably not a fit
Patients who are not receiving a Medtronic InterStim lead, cannot comply with diaries or follow-up visits, or who have conditions outside the inclusion criteria are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial collects electrically evoked pelvic nerve signals at several timepoints during the therapy evaluation period around sacral neuromodulation lead placement. Adults who are candidates for or undergoing Medtronic InterStim lead implantation will have recordings taken alongside standard clinical evaluation and will complete symptom diaries and questionnaires. Data from multiple U.S. sites will be analyzed to identify signal patterns that correlate with clinical response during the evaluation phase. Participants are asked to maintain baseline medication regimens and attend scheduled study visits for signal capture and follow-up.
Why it matters
Potential benefit: If successful, this approach could help clinicians predict which patients will benefit from sacral neuromodulation and speed therapy optimization to reduce ineffective implants.
How similar studies have gone: Sacral neuromodulation is an established treatment, and small research studies have explored electrically evoked pelvic nerve signals, but using these recordings to guide therapy remains experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Overactive Bladder Criteria Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation 6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary. 7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria 1. 18 years of age or older 2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication\* requiring an advanced evaluation 3. Willing and able to provide signed and dated informed consent 4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol 5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation 6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling) Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Exclusion Criteria: Overactive Bladder Criteria Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 12. Women who are pregnant or planning to become pregnant 13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. History of diabetes unless the diabetes is well-controlled through diet and/or medications 6. Have symptomatic urinary tract infection (UTI) 7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 10. Women who are pregnant or planning to become pregnant 11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture) 12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria 1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee) 2. Implanted with a neurostimulator, pacemaker or defibrillator 3. Pelvic floor muscle dysfunction due to surgical intervention or injury 4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia) 5. Have uncorrected high grade internal rectal prolapse 6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months 7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study 8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy 9. Women who are pregnant or planning to become pregnant 10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Where it's running
-
Indiana University Health Methodist Research Institute
Indianapolis, Indiana, United States Recruiting -
Ochsner Clinic Foundation
New Orleans, Louisiana, United States Recruiting -
Mayo Clinic Urology/Urogynecology Department
Rochester, Minnesota, United States Recruiting -
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States Recruiting -
OhioHealth Physician's Group Urology
Hilliard, Ohio, United States Recruiting -
LSUHSC Department of Urology
New Orleans, Louisiana, United States Withdrawn
Show 1 more location
-
DHR Health Institute for Research and Development
Edinburg, Texas, United States Completed
Study contacts
- Study coordinator: Katherine Peterson
- Email: katherine.r.peterson@medtronic.com
- Phone: 414-704-4065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigational Intermittent Catheter: First Look at Safety and Usability
This study tests a new intermittent catheter in adult men who already self-catheterize to see if it is safe and easy to use compared with their current catheter.
-
Flyte device to help urinary incontinence after pelvic radiation for endometrial or cervical cancer
This study tests whether a home-use Flyte device, used during guided pelvic floor exercises, can improve urinary incontinence in women who had pelvic radiation for endometrial or cervical cancer.
-
Self-Start Macrobid for post-Botox lower urinary symptoms
This study tests whether giving a standing prescription for Macrobid after Botox treatment reduces urgent calls, messages, and visits for urinary symptoms compared with usual triage care.
-
Active vs. Passive Anal Sphincter Training in Fecal Incontinence
This home-based trial tests whether adding active sphincter contractions to electrical stimulation helps adults with fecal incontinence more than stimulation alone.
-
How catheter duration affects outcomes after laser prostate surgery for urinary retention
This study tests whether how long a patient has a urinary catheter before laser prostate surgery influences the results of the procedure for men with urinary retention.
-
Beta-glucan cream added to standard skin care for IAD in hospitalized adults
This study tests whether adding a 0.5% beta-glucan moisturizing cream to usual skin care helps adults with incontinence-associated dermatitis heal faster and feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.